GSK Partners with ABL Bio in $2.7B Deal to Develop CNS Therapeutics Using Grabody-B Platform

4Month7Day,GSK(GSK)Announcement with ABL Bio, Inc.ABL BioReach a global licensing agreement in the field of neurodegenerative diseases. Through this agreement,GSKWill be able to useABL BioBlood-brain barrier（BBB）Delivery PlatformGrabody-BDevelopment of new drugs for neurodegenerative diseases, including antibodies, polynucleotides or oligonucleotides, such assiRNAAndASO。

According to the agreement,ABL BioWill receive up to7710Million pounds of advance payment and recent payment, including3850An upfront payment in the millions of pounds, research milestones, and potential project expansion. The eligibility for up to20.75Billion pounds（26.7(Billion USD)Research, development, regulatory, and commercialization milestone payments. If the product is successfully commercialized,ABL BioWill receive tiered royalties on net sales. As part of the agreement,ABL BioWill putGrabody-BRelevant technologies and proprietary technology transfer toGSK, andGSKWill be responsible for preclinical and clinical development, manufacturing, and commercialization.

AboutABL Bio

ABL BioIs a company focused on bispecific antibodies（BsAb）and innovative drug research and development biotechnology company, with core R&D directions including cancer immunotherapy and neurodegenerative disease treatment. In response to the above disease areas,ABL BioThere are two technical platforms, respectivelyGrabody-TPlatform andGrabody-B。

Among themGrabody-BCan be achievedMaximizing Blood-Brain Barrier Penetration（BBB），DevelopmentTreatment of Various Neurological DisordersDrugThe blood-brain barrier, as a protective barrier, restricts the entry of harmful substances and agents into the brain, and is considered a significant obstacle in the development of treatments for neurological disorders.

Grabody-BThe platform is based on insulin-like growth factor1Receptor（IGF1R）As the goal, through non-neutralizing anti-IGF1RAntibodies as molecular shuttles significantly enhance the blood-brain barrier permeability of therapeutic antibodies. Preclinical studies have shown,Grabody-BSignificantly enhances the blood-brain barrier permeability of various therapeutic antibodies in rodents and non-human primates without interference.IGF1RSignal transduction, with superior efficacy or pharmacodynamic effects.

ABL BioUtilizeGrabody-BThe platform has been developedABL301, which is a targeted α-Synuclein andIGF1RPreclinical bispecific antibody for the treatment of Parkinson's disease and other potential indications with enhanced blood-brain barrier penetrability.

In preclinical studies,ABL301Anti-α-The synuclein domain exhibits strong recognition capability and high affinity for pathological aggregates, as well as monomeric α.-The affinity of synuclein is extremely low.

2022Year1Month,ABL BioEntered into a global exclusive cooperation and licensing agreement with Sanofi to jointly develop and commercializeABL301。

ABL BioBased on“Grabody”PlatformDevelop various clinical and non-clinical assets, includingABL301、ABL001（tovecimig）、ABL111（givastomig）、ABL503（ragistomig）、ABL105、ABL202AndABL103Including7Clinical projects for individual pipelines are being conducted in multiple countries to treat various indications.。

GSKNeuroscience Field Layout

GSKResearchSenior Vice President of Research TechnologyChristopher AustinIndicates:"Due to the aging population, the prevalence of neurodegenerative brain diseases is rapidly increasing, and there is an urgent need for new therapies to treat these conditions. Many innovative therapies currently involve antibodies, which, if unable to cross..."BBB, they cannot effectively reach the brain. This agreement reflectsGSKCommitted to innovative platform technology to overcomeBBB, thereby opening new opportunities for treating these devastating diseases, which is alsoGSK"An important part of the emerging product pipeline."

Recently, there has been activity in the field of neuroscience transactions.GSKThe figure.

2024Year11Month,GSKAndVesalius TherapeuticsEstablish a Multi-Target Strategic Alliance to Develop New Therapies for Parkinson's Disease and Neurodegenerative Disorders；2024Year11Month,GSKIn14Acquisition of Neurotechnology Company for $ BillionAliada Therapeutics, to acquire its blood-brain barrier penetration technology and Alzheimer's disease candidate drugALIA-1758；2024Year12Month,GSKAndMuna TherapeuticsReach cooperation and utilize itsMiND-MAPPlatform Discovers and Validates Innovative Drug Targets for Alzheimer's Disease.

AlthoughGSKOnce underwent strategic adjustments, scaling back its neuroscience pipeline, but judging from recent collaboration trends,GSKHas not completely abandoned the field of neuroscience.

1.ABL BioOfficial Website